biological features of cd5+ cd19+ b1 cell and natural igm (vh4-34) in chronic lymphocytic leukemia vs. multiple sclerosis

Chronic lymphocytic leukemia (cll) is the clonal expansion of mature cd5+ b cells and the most common lymphoproliferative disease in adults (b1-cll). b1 cells' anti-inflammatory effects include the production of natural igm (nigm) by the spleen and bone marrow, decreased inflammatory cytokines as a primary response to maintaining tissue homeostasis, and enhanced release of transforming growth factor β (tgfβ). we used the flow cytometry technique in peripheral blood from patients with cll and multiple sclerosis (ms) to immunophenotype b cells and their subpopulations. whole blood from cll and ms patients, as well as healthy controls, was used to detect nigm using the vh4-34 gene copy number and real-time rt-pcr. we found that the proportion of cd5+ b cells was significantly lower in ms patients than in the control group and that cd5+ b lymphocytes were significantly higher in cll patients than in the control group. compared to the control group, cll patients had significantly higher levels of the vh4-34 gene copy number. on the contrary, ms patients had significantly lower vh4-34 gene copy number levels compared to the control group. as the number of antibodies in cll patients increases due to the high number of b1 cells, we propose a new way to treat ms by extracting this natural antibody from the sera of cll patients and injecting it into ms patients.